Almost all cervical cancers are HPV-driven, and virus-induced cancers are generally attractive targets for immunotherapy because viral proteins are strong immune stimulants.38 Indeed, immunotherapies targeting the PD-1/PD-L1 axis have provided long-lasting responses for some patients suffering from aggressive cervical cancer, yet the vast majority experience no clinical benefit. The gene discussed is CD274; the disease is cervical carcinoma.